Biosimilars in China Tipping the balance: risks and opportunities in biosimilars Fuelled by changing epidemiology, reimbursement incentives and advancement of the local pharmaceutical industry, the emerging country biosimilar market has been taking an increasingly large share of the global market. So, what lies in store for multinational pharmaceutical companies (MNCs)? What are the real opportunities and risks in entering these markets and how can the fomer be optimised and the latter minimised? China, with a burgeoning biosimilar market, has been on top of the strategic agenda for MNCs. However, fierce local competition, lengthy registration processes and unfamiliarity with the country's commercialisation channels have deterred many Western entrants. So, what potential strategies are needed to unlock the opportunities the Chinese biosimilar market presents in the local and global perspective while minimising imminent risks?